• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet up on Q2 sales beat, raised full-year guidance

August 5, 2022 By Sean Whooley

Insulet Omnipod 5 Dexcom G6
Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]
Insulet (Nasdaq:PODD) stock is up today — a day after releasing Q2 results that blew past the consensus revenue forecast.

The Acton, Massachusetts–based automated insulin delivery technology developer yesterday evening posted losses of $35 million, or 50¢ per share, on sales of $299.4 million for the three months ended June 30, 2022, for a $10 million bottom-line slide deeper into the red on sales growth of 13.8%.

Analysts on Wall Street had been looking for revenues of $291.5 million, giving Insulet a nearly $8 million sales beat.

Total Omnipod automated insulin delivery system revenue came in at $285.8 million, an increase of 18.1% from 2021. Sales for Omnipod in the U.S. totaled $196.4 million, representing an increase of 30.5% year-over-year. Earlier this week, the company announced the full market launch of the latest-generation Omnipod 5 device in U.S. pharmacies.

“Our second quarter results demonstrate continued momentum in our business and strong execution by the entire Insulet team,” Insulet President and CEO Jim Hollingshead said in a news release. “We achieved a number of recent milestones, including the Omnipod 5 U.S. full market release through retail pharmacies, the progression of our regulatory approval efforts for Omnipod 5 to expand its U.S. indication down to age two and to secure international CE Mark, and the advancement of our plan to further strengthen our manufacturing capabilities through a new Malaysia facility.

“Looking ahead, we’re focused on building on our success and are in a strong position to execute our mission to simplify and improve the lives of people with diabetes around the world.”

Insulet’s previous revenue growth guidance range was for between 12% and 16% year-over-year but, based on its recent results, it is increasing its outlook to between 14% and 17%.

Shares of PODD were up about 7% to $273.94 apiece in morning trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly.

BTIG analyst Marie Thibault wrote in a report that Insulet maintains a “Buy” rating based on its latest financial results, despite margins coming in below expectations.

“While we expect the margin profile will remain pressured over the near term, we think this can be partially offset with an accelerating top line from the full market release of Omnipod 5 in the U.S. and potential launch in Europe in mid-2023 (pending regulatory approval),” she said.

This story originally ran Aug. 4, 2022. Updated Aug. 5 with the next-day stock price. 

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology Tagged With: Insulet

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS